Background.This study reports incremental cost-utility of sibutramine compared to diet and lifestyle advice for the treatment of obesity.Method.The model estimates the costs and quality of life benefits associated with weight loss itself and the reduced incidence of coronary heart disease (CHD) and diabetes in the “healthy obese.” The key source of effectiveness data is 2 randomized controlled trials over 12 months. Utility gain per kilogram lost is analyzed using Short Form–36 data from sibutramine trials. The impact on CHD is estimated using the Framingham risk equation, which relates age/sex/body mass index to risk of heart disease. The reduced incidence of diabetes due to weight loss is estimated from published literature. A life tables approach was used to calculate the cost per quality-adjusted life year (QALY) of 1 year’s treatment with sibutramine compared to diet and lifestyle advice.Results.The incremental cost per QALY of sibutramine is £4780. Sensitivity analyses show that this result is sensitive to utility associated with weight loss and the frequency of monitoring.Conclusions. Sibutramine is a costeffective treatment for obesity when combined with diet and lifestyle advice.
2. West R. Obesity. London: London Office for Health Economics; 1994.
3.
3. Chan JM, Stamper MJ, Rimm EB, Willett WC, Colditz GA. Obesity fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17(9):961–969.
4.
4. Colditz GA, Walter MBBS, Willcott C, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122(7):481–486.
5.
5. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never smoking overweight US white women aged 40-64 years. Am J Epidemiol. 1995;141(12):1128–1141.
6.
6. Smith IG, Goulder MA. Randomised placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001;50(6):505–512.
7.
7. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356:2119–2125.
9. Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomised trials of sibutramine versus placebo. Am J Managed Care. 2001;7(9):875–883.
10.
10. Heitman BL, Garby L. Patterns of long-term weight changes in overweight developing Danishman and womenaged between 30 and 60 Years. Int J Obes. 1999;23:1074–1078.
11.
11. British National Formulary. British National Formulary43; 2002. Available from: www.bnf.org.uk.
12.
12. Netten A, Dennett J. Unit Costs of Health and Social Care 1998. Canterbury (UK): Personal Social Services Research Unit, University of Kent; 1998.
13.
13. Department of Health. Financial Matters, Appendix 1, Health Service Cost Index. London: Department of Health; 2000.
14.
14. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Am Heart Anderson Med/Sci Statement. 1991;83(1):356–363.
15.
15. Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil HAW. Coronary event and case fatality rates in an English population: results of the Oxford Myocardial Infarction Incidence Study. Heart. 1998;80(1):40–44.
16.
16. Government Actuary Department. England andWales life tables. Available from: http://www.gad.gov.uk/.
17.
17. Centers for Disease Control and Prevention. National Vital Statistics Report. United States Life Tables. Atlanta (GA): Centers for Disease Control and Prevention; 1998.
18.
18. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736–741.
19.
19. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary heart angiography after acute myocardial infarction. Circulation. 1996;94(5):957–965.
20.
20. Pickin DM. Cost-effectiveness of MHG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart. 1999;82(3):325–332.
21.
21. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81(9):1110–1115.
22.
22. Sjostrom D, Lissner L, Wedel H. Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477–484.
23.
23. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care. 1999;22(8):1266-1266.
24.
24. Resnick HE, Halter JB, Valsania P, Lin X. Differential effects of BMI on diabetes risk among black and white Americans. Diabetes Care. 1998;21(11):1828-1828.
25.
25. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss andmortality in overweight whitemen aged 40-64 years. Am J Epidemiol. 1999;146(6):491–503.
26.
26. De Grauw WJC, Van Den Hoogen HJM, Van De Lisdonk EH, Van Gerwen WHEM, Van Weel C. Control group characteristics and study outcomes: empirical data from a study on mortality of patients with type 2 diabetes mellitus in Dutch general practice. J Epidemiol Community Health. 1998;52(Suppl 1):9s–12s.
27.
27. Hughes D, McGuire A, Elliot H, et al. The cost of obesity in the United Kingdom. J Med Econ. 1999;2:143–153.
28.
28. Brown JB, Nichols GA, Glauber HS, Bakst AW, Schaffer M, Kelleher CC. Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health-System Pharm. 2001;58(2):151–157.
29.
29. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol. 1998;51(11):1115–1129.
31. Laupacis A, Feeny D, Detsky A, Tugwell PX. How attractive does a new technology have to be towarrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146(4):473–481.
32.
32. Paeratakul S, Lovejoy JC, Ryan DH, Bray GA. The relation of gender, race and socioeconomic status to obesity and obesity comorbidities in a sample of US adults. Int J Obes. 2002;26:1205–1210.
